Back to Search
Start Over
Feasibility of Combination Therapy with Nab-paclitaxel Plus Gemcitabine in Patients with Recurrent Pancreatic Cancer
- Source :
- Anticancer Research. 38:6537-6542
- Publication Year :
- 2018
- Publisher :
- Anticancer Research USA Inc., 2018.
-
Abstract
- Background/aim Nab-paclitaxel plus gemcitabine (nab-P+Gem) is one of most reliable and effective regimens for borderline or unresectable pancreatic cancer (PC). However, the feasibility and clinical benefits of this regimen have never been evaluated for patients with recurrent PC after pancreatectomy. The aim of this study was to investigate the feasibility of combination therapy with nab-paclitaxel plus gemcitabine (nab-P+Gem) for patients with recurrent PC. Patients and methods Twenty-two patients with recurrent PC received an intravenous infusion of nab-P (125 mg/m2) and Gem (1,000 mg/m2) on days 1, 8, and 15 of a 4-week cycle. The primary end-point of this study was completion of the 4 cycles. The secondary end-points were the safety, efficacy, and disease control rate. Results The treatment completion rate of the 4 cycles was 90.9%. The objective response rate was 13.6% and the disease control rate was 63.6%. The median progression-free survival was 7.2 months. The most common grade 3 or higher hematological toxicity was neutropenia (72.7%). There was no treatment-related death. Furthermore, the chemotherapeutic effects varied with the time of recurrence. Conclusion Combination nab-P+Gem therapy was well-tolerated and effective in patients with recurrent PC.
- Subjects :
- Male
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Paclitaxel
Combination therapy
medicine.medical_treatment
Neutropenia
Deoxycytidine
Disease-Free Survival
03 medical and health sciences
0302 clinical medicine
Albumins
Pancreatic cancer
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Humans
Medicine
In patient
Aged
Nab-paclitaxel
business.industry
General Medicine
Middle Aged
medicine.disease
Gemcitabine
Pancreatic Neoplasms
Regimen
Treatment Outcome
030104 developmental biology
030220 oncology & carcinogenesis
Pancreatectomy
Feasibility Studies
Administration, Intravenous
Female
Neoplasm Recurrence, Local
business
medicine.drug
Subjects
Details
- ISSN :
- 17917530 and 02507005
- Volume :
- 38
- Database :
- OpenAIRE
- Journal :
- Anticancer Research
- Accession number :
- edsair.doi.dedup.....795895d1464329dc1fe0ec86ce1810db